Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Onconetix (ONCO) Cash & Equivalents (2023 - 2025)

Onconetix (ONCO) has disclosed Cash & Equivalents for 2 consecutive years, with $341495.0 as the latest value for Q3 2024.

  • On a quarterly basis, Cash & Equivalents fell 95.54% to $341495.0 in Q3 2024 year-over-year; TTM through Sep 2024 was $341495.0, a 95.54% decrease, with the full-year FY2023 number at $4.6 million, changed N/A from a year prior.
  • Cash & Equivalents was $341495.0 for Q3 2024 at Onconetix, down from $930541.0 in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $21.3 million in Q1 2023 to a low of $341495.0 in Q3 2024.